Loading...
Loading...
GTBP| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 0.0K |
| Gross Profit | 0.0K |
| Operating Expense | 3,906.0K |
| Operating I/L | -3,906.0K |
| Other Income/Expense | 196.0K |
| Interest Income | 105.0K |
| Pretax | -3,710.0K |
| Income Tax Expense | 0.0K |
| Net Income/Loss | -3,710.0K |
GT Biopharma, Inc. is a clinical stage biopharmaceutical company specializing in immuno-oncology products. It focuses on developing and commercializing Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology. The company's lead product, GTB-3550, is in Phase I/II clinical trial for myelodysplastic syndromes, acute myeloid leukemia, and systemic mastocytosis. Additionally, it is developing GTB-3650 and GTB-5550 for myeloid leukemias and B7-H3 positive solid tumors, respectively. GT Biopharma has co-development and license agreements for its TriKE technology. Its revenue model is based on the development and commercialization of these innovative cancer therapies.
